Madrigal Pharmaceuticals, Inc.'s Rezdiffra saw Q2 net sales soar 55% to $212.8M amid strong growth. EU approval expected by ...

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Analysts have recently evaluated Madrigal Pharmaceuticals and provided 12-month price targets. The average target is $497.5, accompanied by a high estimate of $554.00 and a low estimate of $428.00.

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter ...

Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

George Lopez, Jesse Garcia and Al Madrigal are among the new additions to the one-night-only virtual table read of the 2007 ...

Madrigal ended the quarter with $848.1 million in cash, cash equivalents, restricted cash & marketable securities. For background, REZDIFFRA is the first-to-market in MASH.

Montgomery County pharmaceutical company Madrigal is taking its shot at succeeding where many other drug developers have previously failed in what is projected to be a multibillion-dollar market ...

That’s exactly what happened Friday morning when the markets opened—at least for Madrigal, which jumped more than 16% to $283.55. Other companies in the space had more modest bumps, such as ...

Yet the topline results released by Madrigal Pharmaceuticals MDGL 0.70% on Monday looked better than most analysts had expected, sending the stock soaring 220%.